News
On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...
(HealthDay News) — The US Department of Health and Human Services (HHS) and US Food and Drug Administration (FDA) recently announced a plan to remove all petroleum-based synthetic dyes from the nation ...
The primary endpoint was the mean normalcy of diet score on the clinician-rated Performance Status Scale for Head and Neck at 1 year. The mean score was 91.6 in the dose-reduction arm and 92.6 in the ...
The Trump administration has replaced two major federal websites for COVID information with a new page that promotes the theory that SARS-CoV-2 came from a lab in China.
We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited cont ...
Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” ...
The DOJ has sent letters to CHEST and other journals asking that editors answer questions about bias and misinformation.
The combination of toripalimab, nimotuzumab, and chemotherapy showed “promising antitumor activity with acceptable toxicity,” researchers wrote.
Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. Colorectal cancer is a type of cancer that affects the colon or rectum.
During 2018-2022, the average annual percent change in cancer deaths decreased significantly in the overall population. New data suggest that, in recent years, US cancer incidence has generally ...
This move is the latest in a series of attempts by the Trump administration to eliminate DEI/DEIA programs and reduce NIH funding.
CAR T-cell therapy showed encouraging efficacy and good safety in newly diagnosed Ph-positive ALL,” the researchers wrote.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results